Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Eli Lilly shares have climbed in the double digits this year.

By Christy Santhosh and Sriparna Roy Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

By Christy Santhosh and Sriparna Roy Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Some patients dropped out of the trial early because they had lost so much weight.

The pharmaceutical stock can still deliver.